Raymond James & Associates Exact Sciences Corp Transaction History

Raymond James & Associates

$150 Billion
Q2 2024

A detailed history of Raymond James & Associates transactions in Exact Sciences Corp stock. As of the latest transaction made, Raymond James & Associates holds 60,125 shares of EXAS stock, worth $3.94 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

60,125

Previous 64,964 7.45%

Holding current value

$3.94 Million

Previous $4.49 Million 43.38%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 19, 2024	SELL	$41.33 - $74.26 $199,995 - $359,344	-4,839 Reduced 7.45%	60,125 $2.54 Million
Q1 2024 Apr 22, 2024	BUY	$56.27 - $73.77 $114,734 - $150,417	2,039 Added 3.24%	64,964 $4.49 Million
Q4 2023 Jan 16, 2024	BUY	$59.06 - $75.72 $202,575 - $259,719	3,430 Added 5.77%	62,925 $4.66 Million
Q3 2023 Oct 24, 2023	BUY	$65.94 - $99.04 $160,563 - $241,162	2,435 Added 4.27%	59,495 $4.06 Million
Q2 2023 Jul 25, 2023	SELL	$62.68 - $95.05 $105,929 - $160,634	-1,690 Reduced 2.88%	57,060 $5.36 Million
Q1 2023 Apr 14, 2023	SELL	$47.19 - $70.77 $693,881 - $1.04 Million	-14,704 Reduced 20.02%	58,750 $3.98 Million
Q4 2022 Feb 08, 2023	BUY	$30.35 - $53.15 $1,699 - $2,976	56 Added 0.08%	73,454 $3.64 Million
Q3 2022 Oct 25, 2022	SELL	$31.97 - $49.37 $362,955 - $560,497	-11,353 Reduced 13.4%	73,398 $2.39 Million
Q2 2022 Aug 12, 2022	SELL	$35.61 - $76.23 $41,022 - $87,816	-1,152 Reduced 1.34%	84,751 $3.34 Million
Q1 2022 May 11, 2022	BUY	$57.56 - $82.54 $351,231 - $503,659	6,102 Added 7.65%	85,903 $6.01 Million
Q4 2021 Feb 08, 2022	BUY	$72.5 - $100.68 $49,300 - $68,462	680 Added 0.86%	79,801 $6.21 Million
Q3 2021 Nov 02, 2021	BUY	$90.24 - $124.05 $1.27 Million - $1.74 Million	14,033 Added 21.56%	79,121 $7.55 Million
Q2 2021 Aug 11, 2021	BUY	$93.66 - $139.27 $635,670 - $945,225	6,787 Added 11.64%	65,088 $8.09 Million
Q1 2021 May 14, 2021	SELL	$116.57 - $155.01 $1.44 Million - $1.92 Million	-12,392 Reduced 17.53%	58,301 $7.68 Million
Q4 2020 Feb 12, 2021	BUY	$99.61 - $142.12 $1.51 Million - $2.16 Million	15,204 Added 27.4%	70,693 $9.37 Million
Q3 2020 Nov 04, 2020	BUY	$72.92 - $102.01 $25,303 - $35,397	347 Added 0.63%	55,489 $5.66 Million
Q2 2020 Jul 28, 2020	SELL	$55.75 - $92.75 $913,854 - $1.52 Million	-16,392 Reduced 22.91%	55,142 $4.79 Million
Q1 2020 Apr 21, 2020	SELL	$37.9 - $104.44 $940,981 - $2.59 Million	-24,828 Reduced 25.77%	71,534 $4.15 Million
Q4 2019 Feb 12, 2020	BUY	$77.66 - $99.74 $263,578 - $338,517	3,394 Added 3.65%	96,362 $8.91 Million
Q3 2019 Nov 07, 2019	BUY	$90.37 - $122.49 $2.39 Million - $3.24 Million	26,423 Added 39.71%	92,968 $8.4 Million
Q2 2019 Aug 06, 2019	BUY	$89.51 - $118.04 $171,769 - $226,518	1,919 Added 2.97%	66,545 $7.86 Million
Q1 2019 May 06, 2019	BUY	$61.98 - $96.5 $265,522 - $413,406	4,284 Added 7.1%	64,626 $5.6 Million
Q4 2018 Feb 11, 2019	SELL	$56.04 - $82.66 $175,517 - $258,891	-3,132 Reduced 4.93%	60,342 $3.81 Million
Q3 2018 Nov 14, 2018	SELL	$48.29 - $80.6 $747,094 - $1.25 Million	-15,471 Reduced 19.6%	63,474 $5.01 Million
Q2 2018 Aug 14, 2018	SELL	$37.84 - $69.96 $432,057 - $798,803	-11,418 Reduced 12.64%	78,945 $4.72 Million
Q1 2018 May 14, 2018	SELL	$39.82 - $57.53 $335,045 - $484,057	-8,414 Reduced 8.52%	90,363 $3.64 Million
Q4 2017 Feb 14, 2018	BUY	$46.49 - $60.51 $54,300 - $70,675	1,168 Added 1.2%	98,777 $5.19 Million
Q3 2017 Nov 13, 2017	BUY	$37.05 - $47.12 $205,145 - $260,903	5,537 Added 6.01%	97,609 $4.6 Million
Q2 2017 Aug 14, 2017	BUY	N/A	92,072	92,072 $3.26 Million

Others Institutions Holding EXAS

# of Institutions

610

Shares Held

166M

Call Options Held

1.93M

Put Options Held

1.23M

View Full List

About EXACT SCIENCES CORP

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $11.6B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

More about EXAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Exact Sciences Corp Transaction History